UniProtKB/Swiss-Prot P21817 : Variant p.Cys35Arg
Ryanodine receptor 1
Gene: RYR1
Feedback ?
Variant information
Variant position:
35
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Cysteine (C) to Arginine (R) at position 35 (C35R, p.Cys35Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and polar (C) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In MHS1; increases calcium-induced calcium release activity.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
35
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
5038
The length of the canonical sequence.
Location on the sequence:
TDDEVVLQCSATVLKEQLKL
C LAAEGFGNRLCFLEPTSNAQ
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human TDDEVVLQCSATVLKEQLKLC LAAEGFGNRLCFLEPTSNAQ
Mouse TDDEVVLQCSATVLKEQLKLC LAAEGFGNRLCFLEPTSNAQ
Rat TDDEVVLQCSATVLKEQLKLC LAAEGFGNRLCFLEPTSNAQ
Pig TDDEVVLQCNATVLKEQLKLC LAAEGFGNRLCFLEPTSNAQ
Rabbit TDDEVVLQCSATVLKEQLKLC LAAEGFGNRLCFLEPTSNAQ
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 5038
Ryanodine receptor 1
Topological domain
1 – 4559
Cytoplasmic
Literature citations
Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred.
Lynch P.J.; Krivosic-Horber R.; Reyford H.; Monnier N.; Quane K.A.; Adnet P.; Haudecoeur G.; Krivosic I.; McCarthy T.V.; Lunardi J.;
Anesthesiology 86:620-626(1997)
Cited for: VARIANT MHS1 ARG-35;
Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
Monnier N.; Kozak-Ribbens G.; Krivosic-Horber R.; Nivoche Y.; Qi D.; Kraev N.; Loke J.; Sharma P.; Tegazzin V.; Figarella-Branger D.; Romero N.; Mezin P.; Bendahan D.; Payen J.-F.; Depret T.; Maclennan D.H.; Lunardi J.;
Hum. Mutat. 26:413-425(2005)
Cited for: VARIANTS MHS1 ARG-35; CYS-163; LEU-163; ARG-165; ASN-166; CYS-177; CYS-178; VAL-227; ARG-248; TRP-328; ARG-341; SER-401; HIS-401; MET-403; SER-522; TRP-552; CYS-614; LEU-614; CYS-2163; HIS-2163; MET-2168; MET-2206; ARG-2206; ASP-2344; MET-2346; THR-2350; THR-2428; ARG-2434; HIS-2435; CYS-2454; HIS-2454; CYS-2458; MET-3916; SER-4684; GLN-4737; TRP-4737; ILE-4826; VAL-4838; ILE-4849; ARG-4876; GLU-4939 AND LEU-4973; VARIANTS TRP-2676 AND SER-2787; CHARACTERIZATION OF VARIANTS MHS1 LEU-163; MET-2206; THR-2428; CYS-2454 AND HIS-2454; FUNCTION; TRANSPORTER ACTIVITY; ACTIVITY REGULATION;
Divergent activity profiles of type 1 ryanodine receptor channels carrying malignant hyperthermia and central core disease mutations in the amino-terminal Region.
Murayama T.; Kurebayashi N.; Yamazawa T.; Oyamada H.; Suzuki J.; Kanemaru K.; Oguchi K.; Iino M.; Sakurai T.;
PLoS ONE 10:E0130606-E0130606(2015)
Cited for: CHARACTERIZATION OF VARIANTS MHS1 ARG-35; CYS-163; LEU-163; ARG-248; ARG-341; CYS-401; HIS-401; SER-522; CYS-614 AND LEU-614; MUTAGENESIS OF TYR-522;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.